Our search identified 4996 potentially relevant articles (Figure 1). We found 10 trials (4–13) with a total of 10 648 patients that fulfilled our inclusion criteria (Table 1). The FRISC-II (FRagmin and Fast Revascularisation during InStability in Coronary artery disease II) study was the largest trial, with 2457 patients (4). The TIMI IIIB (Thrombolysis in Myocardial Ischemia IIIB) study (10), published in 1995, was the earliest trial. Of the 10 trials, 6 reported their maximum follow-up after 2000. All trials had 2 parallel groups except the FRISC-II and TIMI IIIB trials, which had factorial designs that tested other interventions. Four trials (7–8, 10, 13) were funded by noncommercial entities, 2 trials (5, 12) were jointly funded by commercial and noncommercial entities, 2 trials (4, 9) were funded by the pharmaceutical industry, and 2 trials (6, 11) did not report funding sources. Five trials (4–5, 8, 11, 13) were done in Europe, and 4 (6, 9–10, 12) were done in North America. Only 1 small trial (7) included patients from South Africa and South Asia. All trials recruited patients from multiple emergency departments or hospitals. One trial (11) enrolled only hospitalized patients from coronary care units.